Multicentric Prospective Validation of a Universal Test to Quantify Apixaban, Rivaroxaban, Danaparoid and Fondaparinux Levels

Launched by NANTES UNIVERSITY HOSPITAL · Sep 1, 2020

Keywords

ClinConnect Summary

This clinical trial is looking at a new way to measure the levels of certain blood-thinning medications, specifically apixaban, rivaroxaban, danaparoid, and fondaparinux. These medications are important for preventing blood clots in conditions like venous thromboembolism (blood clots in veins) and atrial fibrillation (an irregular heartbeat). The researchers want to see if a commonly used test for heparin, another type of blood thinner, can also effectively measure these other medications.

To participate in this trial, you need to be an adult who is currently being treated with one of these medications. However, if you are receiving unfractionated heparin or low molecular weight heparin, you won’t be eligible. If you join the trial, you will provide a blood sample, which will help the researchers understand how well the heparin test can work for these other medications. This study is currently recruiting participants, and it welcomes people of all genders within the age range of 65 to 74 years.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • Blood sample from adult patients treated with apixaban or rivaroxaban or danaparoid or fondaparinux
• Exclusion Criteria :
• • Patients treated with unfractionated heparin or low molecular weight heparin